Services
Online Inquiry
For research use only. Not intended for any clinical use.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Non-Human Primate (NHP) ADA/Immunogenicity Test Services
Are you facing challenges with unpredictable preclinical data and the interference of immunogenicity in your drug development programs? Creative Biolabs' NHP ADA & Neutralizing Antibody (NAb) Assays help you obtain reliable and translatable immunogenicity data, ensuring accurate toxicokinetic and safety assessments. Our advanced platforms and expertise in non-human primate models provide the precise insights you need to make informed decisions and accelerate your biopharmaceutical pipeline. Let us help you navigate the complexities of immunogenicity.
Introduction to NHP ADA & Neutralizing Antibody Assays
The development of biopharmaceuticals, such as monoclonal antibodies, presents a unique challenge: the potential for the host's immune system to recognize the drug as foreign, leading to immunogenicity. This response can create anti-drug antibodies (ADAs), and a critical subset of these, neutralizing antibodies (NAbs), can inhibit the drug's efficacy. Non-human primates (NHPs) are the most relevant preclinical model for this assessment due to their close genetic and immunological similarities to humans, with genetic homology up to 94.7%.
What Our Service Is
Creative Biolabs provides a comprehensive suite of immunogenicity testing services, including ADA and NAb assays, designed to detect, characterize, and quantify the immune response to your biotherapeutic. These services are crucial for preclinical safety and efficacy studies, as the presence of ADAs can alter a drug's pharmacokinetics (PK) and toxicokinetics (TK), making it difficult to interpret study results. Our services are applicable in several key scenarios, including:
- Preclinical Safety Assessment: ADAs can cause unexpected changes in drug exposure, which may complicate the interpretation of safety data. Our assays provide a critical tool for understanding these changes and their impact on safety.
- Biotherapeutic Candidate Selection: By screening for immunogenicity early in the development pipeline, you can select candidates with a lower risk of an immune response, improving the likelihood of a successful clinical outcome.
- Pharmacokinetic/Toxicokinetic (PK/TK) Analysis: The presence of ADAs can accelerate drug clearance. Our assays allow for the accurate correlation of PK/TK profiles with the host's immune response, providing a clearer picture of drug exposure and its effects.
Why Choose Us?
Partnering with Creative Biolabs addresses key pain points in preclinical development by delivering tangible benefits:
-
Pain Point: The use of less relevant animal models often yields data with poor translatability to humans.
- Our Solution: We leverage the biological and genetic similarities of NHPs to provide immunogenicity data that is more predictive of the human response. Published data demonstrates that NHP immunogenicity can be a more relevant indicator compared to other preclinical species, improving the reliability of your preclinical data package.
-
Pain Point: Immunogenicity can interfere with accurate TK analysis, making it difficult to assess drug safety.
- Our Solution: Our validated assays provide the tools to precisely measure ADA formation. This data allows for the accurate interpretation of TK profiles, helping you distinguish between drug-related effects and those caused by an immune response.
Key Benefits of Our Service
Creative Biolabs' NHP ADA & NAb Assay services are distinguished by a commitment to quality, speed, and scientific rigor. Our unique advantages are designed to accelerate your project timelines and deliver unparalleled value.
- Customization: We don't believe in a one-size-fits-all approach. Every biologic is unique, and so is its potential immunogenicity. We develop and validate custom assays tailored to your specific molecule and study design.
- Response Speed: Our streamlined processes and dedicated team ensure a fast turnaround time (TAT) for your results, keeping your project on track. We understand the importance of speed in a competitive landscape.
- Extensive NHP Resources: As a leader in preclinical services, we have established access to high-quality NHP resources, ensuring consistency and reliability across your studies.
- In-Depth Reporting: Our deliverables go beyond raw data. You receive a comprehensive, report with expert analysis and actionable insights, empowering you to make confident decisions.
How Creative Biolabs' NHP Services Can Assist Your Project?
Our NHP ADA & NAb Assay services are designed as a clear and transparent process, ensuring you are informed at every stage, from initial consultation to final data delivery.
01
Required Starting Materials
02
Consultation & Study Design
03
Assay Development & Validation
04
Sample Analysis & Data Collection
05
Data Interpretation & Reporting
Key Deliverables
- Formal laboratory report
- Raw data files
- Final summary report with expert interpretation
- Method validation report
Capabilities & Partnerships
Service-Specific Data
- Annual Sample Size: Over 50,000 samples analyzed per year.
- Turnaround Time (TAT): Typical turnaround of 2 weeks for bioanalytical results.
- Study Pass Rate: 99%+ success rate in meeting study endpoints.
Our Valued Partners
Frequently Asked Questions
Q: Why should I use an NHP model over other species for immunogenicity testing?
A: NHPs are genetically and immunologically the closest animal model to humans, making them highly relevant for predicting an immune response. While no animal model is perfect, data from NHPs provides more translatable insights than rodent models, helping you mitigate risk before entering clinical trials.
Q: How do you handle drug interference in samples?
A: Drug interference is a common challenge. Our assay validation process is specifically designed to assess and mitigate drug tolerance. We utilize advanced techniques like acid dissociation and have validated our methods against high drug concentrations to ensure we can accurately detect ADAs even in the presence of the drug.
Q: Can your services detect both ADAs and NAbs?
A: Yes, our multi-tiered approach is designed to detect both. We first perform a highly sensitive ADA screening assay. Any positive samples are then confirmed and titered. Subsequently, we use a cell-based or ligand-binding assay to specifically assess the neutralizing activity of the antibodies, providing a complete picture of the immune response.
Q: What factors can influence the immunogenicity of my biologic in an NHP model?
A: Several factors can influence immunogenicity, including the molecule's structure, post-translational modifications, and even formulation. Our experts will discuss these factors with you during the initial consultation to design a study that accounts for these variables and provides the most meaningful data.
Q: How does your approach compare to in-house immunogenicity testing?
A: While in-house testing provides control, partnering with Creative Biolabs offers access to specialized expertise, advanced technology, and dedicated NHP resources without the significant capital investment. We accelerate your timelines and provide a robust, regulatory-compliant data package, allowing your internal team to focus on core research and development.
Contact Us
Creative Biolabs is your trusted partner for NHP ADA & NAb Assays, providing a comprehensive, expert-driven solution for preclinical immunogenicity testing. We combine a deep understanding of biopharmaceutical development with a rigorous, transparent workflow to deliver the accurate, reliable data you need to progress your pipeline with confidence. Contact our team today for more information and to discuss how our services can be tailored to meet your specific project needs. We are ready to assist you in accelerating your path to the clinic.